STAG2 Antibody

What is STAG2 and why is it important in research?

STAG2 is a component of the cohesin complex, essential for sister chromatid cohesion after DNA replication. The cohesin complex plays critical roles in chromosome segregation, DNA repair, and regulation of gene expression through chromatin organization. STAG2 has gained significant research interest due to its frequent mutation in various cancers, particularly bladder cancer, Ewing sarcoma, and glioblastoma. Loss of STAG2 function can significantly alter 3D genome organization, affecting enhancer-promoter interactions and transcriptional programs . Understanding STAG2 function requires reliable antibodies for protein detection in various experimental contexts.

What applications are STAG2 antibodies validated for?

STAG2 antibodies have been validated for multiple applications with specific recommended dilutions:

When selecting an antibody, researchers should consider the specific application requirements and whether validation data exists for their model system .

How do I determine the appropriate antibody for detecting endogenous STAG2?

For detecting endogenous STAG2, select antibodies with demonstrated sensitivity for detecting the protein at its expected molecular weight (approximately 141 kDa). Commercial STAG2 antibodies from reputable suppliers are typically validated using endogenous protein . Critical factors to consider:

• Species cross-reactivity: Ensure the antibody detects STAG2 in your experimental organism (human, mouse, rat)

• Detection method compatibility: Verify the antibody works with your detection system

• Epitope location: For mutation analysis, knowing which protein region the antibody targets is crucial

• Validation evidence: Look for antibodies tested in multiple cell lines relevant to your research

Some STAG2 antibodies target C-terminal epitopes, which is particularly useful when studying truncating mutations that result in the absence of C-terminal regions .

What are the optimal conditions for using STAG2 antibodies in immunohistochemistry?

For optimal IHC conditions with STAG2 antibodies:

• Fixation and antigen retrieval: Most protocols recommend antigen retrieval with TE buffer pH 9.0, though citrate buffer pH 6.0 can serve as an alternative .

• Antibody dilution: Start with 1:20-1:200 dilution range, optimizing based on your specific tissue and antibody .

• Controls: Include positive controls from tissues with known STAG2 expression (e.g., cervical cancer tissue) and negative controls.

• Validation approach: STAG2 immunostaining has been extensively validated in studies of bladder cancer and other tumor types, often using gene-edited isogenic cell lines as controls .

• Interpretation: Nuclear staining is expected, with complete loss of staining indicating STAG2 inactivation.

For bladder cancer studies specifically, STAG2 IHC serves as a reliable biomarker since 85% of tumor-derived mutations result in truncated protein with absence of C-terminus epitope recognition .

How should STAG2 antibodies be stored and handled to maintain optimal activity?

For maintaining STAG2 antibody performance:

• Storage conditions: Store at -20°C, where most formulations remain stable for one year after shipment .

• Buffer composition: Most commercial antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Aliquoting: For antibodies stored at -20°C, aliquoting is generally unnecessary, though it can reduce freeze-thaw cycles for frequently used antibodies .

• Handling precautions: Avoid repeated freeze-thaw cycles and keep on ice while using.

• Working dilutions: Prepare fresh working dilutions on the day of experiment.

Some smaller volume formats (20μl) may contain 0.1% BSA as a stabilizer, which should be considered when designing experiments sensitive to BSA presence .

What methodological considerations are important when using STAG2 antibodies for distinguishing wildtype from mutant STAG2?

When distinguishing wildtype from mutant STAG2:

• Epitope location: Use antibodies targeting regions frequently lost in truncating mutations (e.g., C-terminus) .

• Isogenic controls: Include STAG2-proficient and STAG2-deficient cell lines as controls. Gene-edited isogenic cell sets serve as excellent validation tools .

• Multiple detection methods: Confirm IHC findings with alternative methods like western blotting.

• Binary interpretation: STAG2 staining in tumor cells is often interpreted as a binary variable (present/absent) rather than by staining intensity .

• Context-specific validation: For certain tissue types, optimize staining protocols and validate against known mutation status.

This approach has been successfully employed in clinical studies of bladder cancer, where STAG2 immunostaining accurately identified tumors with genetic inactivation of STAG2 .

How does STAG2 loss affect cancer progression, and how can antibodies help study this phenomenon?

STAG2 loss demonstrates context-dependent effects on cancer progression:

These findings suggest a noncanonical function of STAG2 in promoting cell motility and invasion in certain cancer contexts, which can be effectively studied using qualified STAG2 antibodies .

What is the relationship between STAG2 mutation status and patient outcomes in cancer, and how can antibodies be used for prognostication?

The relationship between STAG2 status and outcomes is cancer-type dependent:

• Bladder cancer prognostication:

  • In NMIBC: STAG2-deficient tumors show lower recurrence rates (25% vs 52%), with STAG2 expression being an independent predictor of recurrence (HR=2.4; p=0.05)

  • In MIBC: STAG2 deficiency associates with improved survival outcomes

• Antibody-based biomarker applications:

  • IHC for STAG2 provides a cost-effective prognostic biomarker

  • Multivariable analysis confirms STAG2 as an independent predictor of progression (HR=1.86; p=0.05)

  • STAG2 IHC can help stratify patients for different treatment approaches

• Technical advantages:

  • STAG2 is on the X-chromosome, so only a single mutation is required for complete inactivation

  • 85% of STAG2 mutations are truncating, resulting in complete absence of C-terminal epitopes

  • STAG2 is highly abundant in the proteome, making antibody detection reliable

This approach has been validated in multiple independent cohorts, demonstrating the clinical utility of STAG2 antibodies for cancer prognostication .

How does STAG2 loss affect chromatin interactions and gene expression, and what experimental approaches can detect these changes?

STAG2 loss profoundly alters 3D genome organization:

• Cohesin complex redistribution:

  • STAG2 depletion leads to significant changes in genomic binding of cohesin components

  • STAG1 and SMC1A binding increases in most regions, but fails to replace STAG2 around certain enhancers and promoters

• Chromatin loop dynamics:

  • STAG2 mutation results in both gain and loss of specific chromatin loops

  • In glioblastoma models, correction of mutant STAG2 creates cell line-specific loop changes

  • Some loops are shared between different cell systems (9.0-fold higher than expected by chance alone)

• Experimental approaches:

  • HiChIP with SMC1A antibodies to profile global chromatin conformation

  • RNA-seq to identify transcriptional changes

  • ChIP-seq with antibodies against STAG1, STAG2, and other cohesin components

  • H3K27me3 ChIP-seq to assess Polycomb-mediated repression changes

• Context-specific effects:

  • STAG2 correction dramatically affects PcG signaling in some GBM cell lines (H4) but not others (42MGBA)

  • Acute inactivation of STAG2 in LN229 cells increases H3K27me3 mark

These findings indicate that STAG2's role in genome organization is complex and context-dependent, requiring multiple complementary experimental approaches for comprehensive characterization .

What are the considerations when using STAG2 antibodies in ChIP experiments to study chromatin interactions?

For ChIP experiments with STAG2 antibodies:

• Antibody selection criteria:

  • Use antibodies specifically validated for ChIP applications

  • Ensure high specificity and low background

  • Consider using multiple antibodies targeting different STAG2 epitopes to confirm findings

• Experimental controls:

  • Include IgG controls to assess non-specific binding

  • Use STAG2-deficient cells as negative controls

  • Consider performing parallel ChIP with antibodies against other cohesin components (SMC1A, STAG1) for comparative analysis

• Cross-validation approaches:

  • Combine ChIP-seq with other methods like HiChIP or Hi-C

  • Validate key findings with orthogonal techniques like 3C/4C

  • Correlate binding patterns with expression changes via RNA-seq

• Data analysis considerations:

  • Compare STAG2 binding with enhancer marks (H3K27ac) and promoter marks

  • Analyze co-binding patterns with transcription factors, particularly ETS family factors

  • Examine differential binding between wild-type and mutant conditions

This multi-layered approach enables comprehensive characterization of STAG2's role in chromatin organization and transcriptional regulation .

How can STAG2 antibodies be used in combinatorial studies with other cohesin complex components?

For comprehensive cohesin complex studies:

• Co-IP experiments:

  • Use STAG2 antibodies for immunoprecipitation followed by western blotting for other cohesin components

  • Assess how STAG2 mutations affect interactions with other complex members

  • Compare wild-type and mutant conditions to identify altered protein associations

• Sequential ChIP (ChIP-reChIP):

  • Perform initial ChIP with STAG2 antibodies followed by secondary ChIP with antibodies against other cohesin components

  • Identify genomic regions bound by specific cohesin subcomplexes

  • Compare STAG1-containing versus STAG2-containing cohesin complexes

• Proximity ligation assays:

  • Use STAG2 antibodies in combination with antibodies against other cohesin components

  • Visualize and quantify protein-protein interactions in situ

  • Compare interaction frequencies in different cellular contexts

• Mass spectrometry-based approaches:

  • Immunoprecipitate STAG2 and identify interacting partners

  • Compare interactomes between wild-type and mutant conditions

  • Identify novel STAG2-associated proteins beyond the core cohesin complex

These approaches provide complementary insights into how STAG2 functions within the larger context of the cohesin complex and its associated regulatory factors .

What are common technical challenges when using STAG2 antibodies and how can they be addressed?

Common challenges with STAG2 antibodies include:

• Non-specific bands in Western blotting:

  • Solution: Optimize blocking conditions (5% milk or BSA)

  • Use proper positive controls (e.g., Jurkat, HeLa, K-562, MCF-7 cells) and negative controls (STAG2-knockout cells)

  • Ensure antibody dilution is within recommended range (1:1000-1:4000)

• Variable IHC staining:

  • Solution: Test different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Optimize antibody dilution within recommended range (1:20-1:200)

  • Use positive control tissues with known STAG2 expression

• Cross-reactivity concerns:

  • Solution: Validate specificity using STAG2-deficient cells

  • Consider potential cross-reactivity with STAG1 due to sequence homology

  • Test multiple antibodies targeting different epitopes

• Inconsistent IP results:

  • Solution: Adjust antibody amount (0.5-4.0 μg for 1.0-3.0 mg of protein lysate)

  • Optimize lysis conditions to preserve protein-protein interactions

  • Include appropriate controls to verify specificity

These approaches can help ensure reliable and reproducible results when working with STAG2 antibodies across different experimental conditions.

How can researchers reconcile conflicting data between STAG2 antibody staining and genomic analysis results?

When facing discrepancies between antibody detection and genomic data:

• Verify antibody epitope location:

  • Certain mutations may not affect antibody binding if they occur outside the epitope region

  • C-terminal antibodies won't detect truncating mutations but will detect missense mutations

  • N-terminal antibodies may detect truncated proteins that lack function

• Consider alternative mechanisms of STAG2 loss:

  • Epigenetic silencing can reduce protein without detectable mutations

  • Post-translational modifications may affect antibody recognition

  • Alternative splicing might produce variant proteins with altered epitope availability

• Technical validation approaches:

  • Use multiple antibodies targeting different epitopes

  • Perform RNA analysis to assess transcriptional status

  • Consider protein degradation or stability issues

  • Validate findings in isogenic cell systems with known STAG2 status

• Biological heterogeneity assessment:

  • Evaluate potential tumor heterogeneity through sectioning and staining multiple regions

  • Consider clonal evolution in tumor samples

  • Assess whether genomic analysis and protein detection were performed on the same sample region

These strategic approaches can help resolve apparent contradictions between genomic and protein-level analyses of STAG2 status .

What advanced techniques are being developed for STAG2 antibody design and utilization?

Recent advances in STAG2 antibody technology include:

• De novo antibody design:

  • Computational approaches have enabled design of precise, sensitive, and specific antibodies without prior antibody information

  • Yeast display scFv libraries combining designed light and heavy chain sequences can identify binders with varying binding strengths

  • These methods can yield antibodies with comparable affinity, activity, and developability to commercial antibodies

• Application-specific antibody engineering:

  • Development of antibodies optimized for specific applications (ChIP-seq, HiChIP)

  • Engineering antibodies with increased specificity for distinguishing between STAG1 and STAG2

  • Creation of antibodies targeting specific post-translational modifications of STAG2

• Emerging analytical techniques:

  • Single-cell antibody-based proteomics to assess STAG2 expression heterogeneity

  • Multiplexed imaging approaches for simultaneous detection of STAG2 and other cohesin components

  • Integration of antibody-based detection with genomic and transcriptomic analyses

• Recombinant antibody fragments:

  • Development of smaller antibody formats (Fab, scFv) for specialized applications

  • Engineered antibodies with reduced background for improved signal-to-noise ratio

  • Site-specific conjugation strategies for direct fluorophore labeling

These innovations represent the cutting edge of STAG2 antibody technology, enabling increasingly sophisticated research applications .

How will STAG2 antibodies contribute to future research and potential therapeutic developments?

STAG2 antibodies will continue to play critical roles in advancing research and therapeutic development through:

• Precision medicine applications:

  • Stratification of patients based on STAG2 status for clinical trials

  • Development of companion diagnostics for emerging targeted therapies

  • Monitoring treatment response and resistance mechanisms

• Mechanistic studies:

  • Detailed mapping of altered chromatin architecture in STAG2-deficient cells

  • Understanding context-specific effects of STAG2 loss across different cancer types

  • Elucidating interactions between STAG2 and other cancer-relevant pathways

• Therapeutic development:

  • Identification of synthetic lethal interactions with STAG2 loss

  • Validation of target engagement for drugs designed to exploit STAG2 deficiency

  • Development of antibody-drug conjugates targeting cancer-specific STAG2 variants

• Technological advances:

  • Integration with emerging spatial genomics and proteomics methods

  • Application in high-throughput screening platforms

  • Development of engineered antibodies with enhanced properties